Albumin-based drug delivery using cysteine 34 chemical conjugates; important considerations and requirements

Mikael B.  Caspersen; Matthias Kuhlmann; Karl  Nicholls; Malcolm J.  Saxton; Birgitte  Andersen; Karen  Bunting; Jason  Cameron; Ken Howard

doi:10.4155/tde-2017-0038

Albumin-based drug delivery using cysteine 34 chemical conjugates; important considerations and requirements

Mikael B. Caspersen , Matthias Kuhlmann, Karl Nicholls , Malcolm J. Saxton , Birgitte Andersen , Karen Bunting , Jason Cameron, Ken Howard

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

22 Citations (Scopus)

Abstract

The long blood circulation time of albumin has been clinically utilized as a half-life extension technology for improved drug performance. The availability of one free thiol for site-selective chemical conjugation offers an alternative approach to current genetic fusion and association-based products. This special report highlights important factors for successful conjugation that allows the reader to design and evaluate next-generation albumin conjugates. Albumin type, available conjugation chemistries, linker length, animal models and influence of conjugation on albumin pharmacokinetics and drug activity are discussed.

Original language	English
Journal	Therapeutic Delivery
Volume	8
Issue	7
Pages (from-to)	511-519
Number of pages	9
ISSN	2041-5990
DOIs	https://doi.org/10.4155/tde-2017-0038
Publication status	Published - Jul 2017

Keywords

albumin
conjugation
cysteine 34
half-life extension
in vivo models
neonatal Fc receptor

Access to Document

10.4155/tde-2017-0038

Cite this

@article{6015fad4dd26421e82df97a5fb35d8a8,

title = "Albumin-based drug delivery using cysteine 34 chemical conjugates; important considerations and requirements",

abstract = "The long blood circulation time of albumin has been clinically utilized as a half-life extension technology for improved drug performance. The availability of one free thiol for site-selective chemical conjugation offers an alternative approach to current genetic fusion and association-based products. This special report highlights important factors for successful conjugation that allows the reader to design and evaluate next-generation albumin conjugates. Albumin type, available conjugation chemistries, linker length, animal models and influence of conjugation on albumin pharmacokinetics and drug activity are discussed.",

keywords = "albumin, conjugation, cysteine 34, half-life extension, in vivo models, neonatal Fc receptor",

author = "Caspersen, {Mikael B.} and Matthias Kuhlmann and Karl Nicholls and Saxton, {Malcolm J.} and Birgitte Andersen and Karen Bunting and Jason Cameron and Ken Howard",

year = "2017",

month = jul,

doi = "10.4155/tde-2017-0038",

language = "English",

volume = "8",

pages = "511--519",

journal = "Therapeutic Delivery",

issn = "2041-5990",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

Albumin-based drug delivery using cysteine 34 chemical conjugates; important considerations and requirements. / Caspersen , Mikael B. ; Kuhlmann, Matthias; Nicholls , Karl et al.
In: Therapeutic Delivery, Vol. 8, No. 7, 07.2017, p. 511-519.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Albumin-based drug delivery using cysteine 34 chemical conjugates; important considerations and requirements

AU - Caspersen , Mikael B.

AU - Kuhlmann, Matthias

AU - Nicholls , Karl

AU - Saxton , Malcolm J.

AU - Andersen , Birgitte

AU - Bunting , Karen

AU - Cameron, Jason

AU - Howard, Ken

PY - 2017/7

Y1 - 2017/7

N2 - The long blood circulation time of albumin has been clinically utilized as a half-life extension technology for improved drug performance. The availability of one free thiol for site-selective chemical conjugation offers an alternative approach to current genetic fusion and association-based products. This special report highlights important factors for successful conjugation that allows the reader to design and evaluate next-generation albumin conjugates. Albumin type, available conjugation chemistries, linker length, animal models and influence of conjugation on albumin pharmacokinetics and drug activity are discussed.

AB - The long blood circulation time of albumin has been clinically utilized as a half-life extension technology for improved drug performance. The availability of one free thiol for site-selective chemical conjugation offers an alternative approach to current genetic fusion and association-based products. This special report highlights important factors for successful conjugation that allows the reader to design and evaluate next-generation albumin conjugates. Albumin type, available conjugation chemistries, linker length, animal models and influence of conjugation on albumin pharmacokinetics and drug activity are discussed.

KW - albumin

KW - conjugation

KW - cysteine 34

KW - half-life extension

KW - in vivo models

KW - neonatal Fc receptor

UR - http://www.scopus.com/inward/record.url?scp=85021165101&partnerID=8YFLogxK

U2 - 10.4155/tde-2017-0038

DO - 10.4155/tde-2017-0038

M3 - Journal article

C2 - 28555530

SN - 2041-5990

VL - 8

SP - 511

EP - 519

JO - Therapeutic Delivery

JF - Therapeutic Delivery

IS - 7

ER -

Albumin-based drug delivery using cysteine 34 chemical conjugates; important considerations and requirements

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this